Verona Pharma plc (VRNA)

Verona Pharma plc (VRNA) scores 62 out of 100 on boothcheck's 11-model valuation framework. Verdict: Watch The estimated fair value is $-4.71, representing a 2170% premium to fair value.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full VRNA analysis on boothcheck